Viridian Therapeutics: Paradigm reports 5.1% stake

Viridian Therapeutics, Inc. Schedule 13G reporting beneficial ownership by Paradigm-related entities and an affiliated fund.

Rhea-AI Filing Summary

Viridian Therapeutics, Inc. Schedule 13G reporting beneficial ownership by Paradigm-related entities and an affiliated fund. The filing shows Paradigm BioCapital Advisors (and related reporting persons) beneficially own 5,633,788 shares (5.1%) and Paradigm BioCapital International Fund Ltd. beneficially owns 4,942,532 shares (4.5%), with these figures stated as of June 18, 2026. The filing bases percentages on 110,427,682 shares outstanding as of May 11, 2026.

The Schedule 13G is a passive ownership disclosure identifying voting and dispositive powers for each reporting person and includes a joint filing agreement. The filing disclaims ownership beyond the shares each reporting person directly beneficially owns.

Insights

Corporate Governance Analyst

Passive investor group reports single-digit stakes and discloses voting/dispositive power.

The filing lists 5,633,788 shares attributed to Paradigm BioCapital Advisors and related entities and 4,942,532 shares to Paradigm BioCapital International Fund Ltd., with voting and dispositive power shown on the cover page. Percentages are tied to an issuer-reported 110,427,682 shares outstanding as of May 11, 2026.

Future disclosures in periodic filings may show changes; current statements include a joint filing agreement and disclaimers of broader ownership.

Capital Markets Specialist

Holdings represent modest passive stakes below 10% thresholds commonly associated with control signals.

The combined positions reported—each under 10% of the class—are characterized as passive under the Schedule 13G construct. The cover-page fields show sole voting and dispositive power amounts for each reporting person.

These stakes could still be relevant to liquidity or block trade considerations; any material change in ownership would require updated SEC disclosure.

Key Figures

Paradigm Advisors holdings: 5,633,788 shares Paradigm Advisors ownership %: 5.1% Paradigm International Fund holdings: 4,942,532 shares +2 more

5 metrics

Paradigm Advisors holdings 5,633,788 shares reported as of <date>June 18, 2026</date>

Paradigm Advisors ownership % 5.1% percent of class based on May 11, 2026 outstanding count

Paradigm International Fund holdings 4,942,532 shares reported as of <date>June 18, 2026</date>

Paradigm International Fund ownership % 4.5% percent of class based on May 11, 2026 outstanding count

Shares outstanding used 110,427,682 shares outstanding as of <date>May 11, 2026</date>

Key Terms

Schedule 13G, Beneficially own, Sole Dispositive Power

3 terms

Schedule 13G regulatory

"Item 1. Name of issuer: Viridian Therapeutics, Inc."

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

Beneficially own financial

"The Fund and one or more separately managed accounts managed by the Adviser directly beneficially own the Common Stock"

Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

Sole Dispositive Power regulatory

"7 | Sole Dispositive Power 5,633,788.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Paradigm BioCapital hold in Viridian Therapeutics (VRDN)?

Paradigm BioCapital Advisors and related entities report beneficial ownership of 5,633,788 shares (5.1%). The figure is given as of June 18, 2026 and is shown with sole voting and dispositive power on the cover page.

How many shares does Paradigm BioCapital International Fund Ltd. report owning in VRDN?

The Fund reports beneficial ownership of 4,942,532 shares (4.5%). The filing ties the percentage to 110,427,682 shares outstanding as of May 11, 2026, per the issuer's disclosure.

What share count does the Schedule 13G use as the basis for percentages?

Percentages are based on 110,427,682 shares of common stock outstanding as of May 11, 2026, as reported in the issuer's Prospectus Supplement and Form 8-K referenced in the filing.

Does the filing indicate active control or passive ownership?

The document is a Schedule 13G passive ownership statement filed by reporting persons and includes disclaimers; it does not state active control and treats the positions as direct beneficial ownership by each reporting person.

What powers over the shares are disclosed in the filing?

The cover-page fields show each reporting person with sole voting power and sole dispositive power equal to their reported share amounts (e.g., 5,633,788 shares for Paradigm), with no shared powers listed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/26/2026 - 04:05 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Viridian Therapeutics, Inc.

(Name of Issuer)

Common Stock, $0.01 par value per share

(Title of Class of Securities)

92790C104

(CUSIP Number)

06/18/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 92790C104

1

Names of Reporting Persons

Paradigm BioCapital Advisors LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 5,633,788.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 5,633,788.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,633,788.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.1 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 92790C104

1

Names of Reporting Persons

Paradigm BioCapital Advisors GP LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 5,633,788.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 5,633,788.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,633,788.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.1 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: limited liability company

SCHEDULE 13G

CUSIP Number(s): 92790C104

1

Names of Reporting Persons

Senai Asefaw, M.D.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 5,633,788.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 5,633,788.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,633,788.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.1 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

CUSIP Number(s): 92790C104

1

Names of Reporting Persons

Paradigm BioCapital International Fund Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 4,942,532.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 4,942,532.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,942,532.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.5 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Viridian Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 221 Crescent Street, Suite 103A, Waltham, MA 02453
Item 2.
(a)	Name of person filing: This Schedule 13G is filed by the following (the "Reporting Persons"): (1) Paradigm BioCapital Advisors LP (the "Adviser"); (2) Paradigm BioCapital Advisors GP LLC (the "Adviser GP"); (3) Senai Asefaw, M.D. ("Senai Asefaw"); and (4) Paradigm BioCapital International Fund Ltd. (the "Fund"). The Fund is a private investment vehicle. The Fund and one or more separately managed accounts managed by the Adviser (the "Account") directly beneficially own the Common Stock reported in this statement. The Adviser is the investment manager of the Fund and the Account. The Adviser GP is the general partner of the Adviser. Senai Asefaw is the managing member of the Adviser GP. The Adviser, the Adviser GP and Senai Asefaw may be deemed to beneficially own the Common Stock directly beneficially owned by the Fund and the Account. Each Reporting Person disclaims beneficial ownership with respect to any Common Stock other than the Common Stock directly beneficially owned by such Reporting Person.
(b)	Address or principal business office or, if none, residence: The principal business office of the Fund is c/o Walkers, 190 Elgin Avenue, George Town, Grand Cayman KY1-9001, Cayman Islands. The principal business office of the Adviser, the Adviser GP and Senai Asefaw is 520 Fifth Avenue, 23rd Floor, New York, NY 10036.
(c)	Citizenship: For citizenship or place of organization see Item 4 of the cover page of each Reporting Person.
(d)	Title of class of securities: Common Stock, $0.01 par value per share
(e)	CUSIP Number(s): 92790C104
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See Item 9 on the cover page for each Reporting Person, and Item 2, which information is given as of the close of business on June 18, 2026, the Date of Event which requires the filing of this Schedule 13G.
(b)	Percent of class: See Item 11 on the cover page for each Reporting Person. The percentages of beneficial ownership contained herein are based on 110,427,682 shares of Common Stock outstanding as of May 11, 2026 (after giving effect to the closing of an equity offering by the Issuer on such date), as reported by the Issuer in its Prospectus Supplement filed with the SEC on May 8, 2026 and its Form 8-K filed with the SEC on May 11, 2026.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See Item 5 on the cover page for each Reporting Person.
	(ii) Shared power to vote or to direct the vote: See Item 6 on the cover page for each Reporting Person.
	(iii) Sole power to dispose or to direct the disposition of: See Item 7 on the cover page for each Reporting Person.
	(iv) Shared power to dispose or to direct the disposition of: See Item 8 on the cover page for each Reporting Person.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Paradigm BioCapital Advisors LP

Signature:	/s/ David K. Kim
Name/Title:	David K. Kim / Authorized Signatory
Date:	06/26/2026

Paradigm BioCapital Advisors GP LLC

Signature:	/s/ David K. Kim
Name/Title:	David K. Kim / Authorized Signatory
Date:	06/26/2026

Senai Asefaw, M.D.

Signature:	/s/ Senai Asefaw, M.D.
Name/Title:	N/A
Date:	06/26/2026

Paradigm BioCapital International Fund Ltd.

Signature:	/s/ David K. Kim
Name/Title:	David K. Kim / Authorized Signatory
Date:	06/26/2026

Exhibit Information

Exhibit 99.1 - Joint Filing Agreement